Company Overview

PRIME exits and American HealthCare Capital are pleased to introduce an opportunity to invest in an innovative medical device company that has created a technologically disruptive, patent-protected emergency-use auto-injector on the cusp of FDA approval, as well as life-saving formulations to be used in its auto-injector.  The Company’s first therapeutic indication is using epinephrine in its auto-injector for treating anaphylactic shock, with a plan to displace and ultimately replace EpiPen. The Company is pursuing both civilian (private sector) and military use of its auto-injector.

Financial Overview

The worldwide auto-injector market size was estimated at $54.55 billion in 2021 and is projected to grow at a CAGR of 17.9% during the forecast period 2021-2030. Auto-injectors are usually used for self-administration of epinephrine (to mitigate anaphylaxis), by migraine sufferers who want quick relief of headaches, or even by the military and emergency services workers to combat the effects of nerve agents. North America led the global market in 2022 and accounted for a revenue share of over 30%.

Asking Price

The Company’s founder is looking for a strategic or financial partner to add value through its connections, financial strength, and resources to grow the Company to the next level. Therefore, the founder will consider either minority growth funding of $15 million or possibly a majority equity investment while remaining with the Company to implement the growth opportunities.